Skip to main content
Neogen Chemicals Limited logo

Neogen Chemicals Limited — Investor Relations & Filings

Ticker · NEOGEN ISIN · INE136S01016 LEI · 335800PFY9B77Z2GOK22 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2026-05-16 Regulatory Filings
Country IN India
Listing BSE.NS NEOGEN

About Neogen Chemicals Limited

https://neogenchem.com/

Neogen Chemicals Limited specializes in the development and large-scale manufacturing of bromine-based and lithium-based specialty chemicals. The product portfolio includes a diverse range of bromine derivatives, lithium salts, Grignard reagents, and advanced intermediates. These products serve critical roles in pharmaceutical, agrochemical, and engineering applications. The company has expanded its operations into the energy storage market, focusing on the production of electrolytes and lithium salts for lithium-ion batteries. With a strong emphasis on research and development, the firm provides custom synthesis and contract manufacturing services to global innovators. Manufacturing capabilities are supported by multi-product facilities designed to meet stringent quality standards for complex chemical processes and high-purity requirements.

Recent filings

Filing Released Lang Actions
Dividend
Regulatory Filings Classification · 85% confidence The document is a formal stock‐exchange filing under SEBI LODR Regulations disclosing the outcome of a board meeting. It announces the approval of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, the unmodified auditor’s report (Annexure I & II), a recommended final dividend, changes to the insider‐trading code, and other compliance information. While it contains the auditor’s report and financial results, it is not the full Annual Report (10‐K) nor a pure standalone audit opinion (AR); it also is not simply a press‐style earnings release (ER) but a statutory compliance filing that bundles various disclosures. It therefore falls into the “Regulatory Filings” category as a general listing compliance announcement.
2026-05-16 English
Recommendation of Final Dividend of Re. 1 per equity share subject to approval of shareholders at the ensuing AGM.
Regulatory Filings Classification · 85% confidence The document is a formal compliance announcement filed with the BSE and NSE under SEBI Listing Regulations (Reg. 30, 33, etc.), notifying the outcome of the board meeting, the approval of audited financial results (quarter and full year ended March 31, 2026), and attaching the audit reports. It is not a full Annual Report (10-K), nor merely an earnings highlights release (ER), nor solely an Audit Report (AR), nor a proxy, dividend notice, or any other specific category. It is a regulatory disclosure falling under general Regulatory Filings.
2026-05-16 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 80% confidence The document is a regulatory filing under the SEBI Listing Regulations reporting the outcome of the Board meeting in which the audited financial results (quarter and full year ended March 31, 2026) were approved and accompanied by the independent auditor’s report and related disclosures. It contains actual financial statements and substantive audit opinions rather than merely highlights or a notice of publication. This aligns with the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial statements for a period shorter than a full fiscal year (i.e., quarterly and year-to-date results), and is not a full Annual Report (10-K) nor just a high-level earnings release. FY 2026
2026-05-16 English
Approval of Audited Financial Results (Standalone and Consolidated) of the Company Company along with the Audit Reports for the Quarter and Financial Year ended March 31, 2026 and Asset ....
Regulatory Filings Classification · 84% confidence The document is a formal stock‐exchange filing under SEBI LODR Regulations (Reg.30/33/52 etc.) announcing the outcome of a Board meeting—specifically approval of audited quarterly and year‐end financial results, recommendation of a final dividend, code amendments, borrowing disclosures and project updates. Although an Independent Auditor’s Report is attached as Annexure, the primary purpose of the filing is a regulatory announcement, not the standalone audit report itself or a full interim/quarterly financial statement. Thus it best fits the “Regulatory Filings (RNS)” category as a general compliance announcement.
2026-05-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an intimation under SEBI (LODR) Regulations 30 and 51 notifying stock exchanges of the schedule for an upcoming Q4 FY26 earnings conference call and providing dial-in details and invitation, but it does not include actual financial results or a transcript. This is a regulatory announcement of a call schedule rather than an earnings release (ER) or call transcript (CT), so it falls under general regulatory filings (RNS).
2026-05-12 English
Intimation of Earnings Conference Call scheduled to be held on Monday, May 18, 2026, at 4:30 p.m. IST for analysts/ investors to discuss the results for the quarter and financial year ended ....
Regulatory Filings Classification · 78% confidence The document is an official intimation to stock exchanges under SEBI Listing Regulations announcing the schedule and dial‐in details for an upcoming earnings conference call. It does not contain the actual earnings results, financial statements, or a transcript of the call—only a notice of the call. This fits the “Regulatory Filings” category as a general compliance/regulatory announcement rather than an earnings release, interim report, transcript, or investor presentation.
2026-05-12 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.